The possible mechanism of hypotensive activity of some pyrrolidin-2-one derivatives with antagonist properties at alpha1-adrenoceptors

European Journal of Pharmacology

Volumn 673, Issue 1-3, 2011, Pages 40-48

  Sapa, Jacek ^a   Kubacka, Monika ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Adrenoceptor blocking activity; 1 3 (4 Arylpiperazin 1 yl) 2 hydroxypropyl pyrrolidin 2 one derivative; Hypotensive activity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; EP 40; EP 43; EP 44; EP 46; EP 47; EP 70; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PYRROLIDIN 2 ONE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOASSAY; RAT; RECEPTOR AFFINITY; SINGLE DRUG DOSE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; GUINEA PIGS; MALE; NITRIC OXIDE; PYRROLIDINONES; RABBITS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATION;

EID: 81855207430     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.05.010     Document Type: Article

References (32)

1. O. Arunlakshana, and H.O. Schild Some quantitative uses of drug antagonists Br. J. Pharmacol. 14 1959 48 58
2. G.L. Bakris, J.N. Basile, T.D. Giles, and A.A. Taylor The role of nitric oxide inimproving endothelial function and cardiovascular health: focus on nebivolol Am. J. Med. 123 2010 2 8
3. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
4. S. Chulia, J. Moreau, E. Naline, M.A. Noguera, M.D. Ivorra, M.P. D'Ocón, and C. Advenier The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta Br. J. Pharmacol. 119 1996 1305 1312 (Pubitemid 26402006)
5. P.A. Dabisch, J.T. Liles, S.R. Baber, N.H. Golwala, S.N. Murthy, and P.J. Kadowitz Analysis of L-NAME-dependent and -resistant responses to acetylcholine in the rat Am. J. Physiol. Heart. Circ. Physiol. 294 2008 688 698
6. S.M. Davidson, and M.R. Duchen Effects of NO on mitochondrial function in cardiomyocytes: pathophysiological relevance Cardiovasc. Res. 71 2006 10 21 (Pubitemid 43870058)
7. K.M. Desai, V. Gopalakrishnan, L.M. Hiebert, J.R. McNeill, and T.W. Wilson EDHF-mediated rapid restoration of hypotensive response to acetylcholine after chronic, but not acute, nitric oxide synthase inhibition in rats Eur. J. Pharmacol. 546 2006 120 126 (Pubitemid 44331834)
8. M. Eltze, R. Boer, M.C. Michel, P. Hein, R. Testa, W.R. Ulrich, N. Kolassa, and K.H. Sanders In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha1A- vs. alpha1B- and alpha1D-adrenoceptors Naunyn Schmiedebergs Arch Pharmacol 363 2001 649 662 (Pubitemid 32477273)
9. M. Eltze, T. Grebe, M.C. Michel, P. Czyborra, and B. Ullrich Affinity profile at alpha(1)- and alpha(2)-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine Eur. J. Pharmacol. 443 2002 151 168 (Pubitemid 34603610)
10. J. Handzlik, D. Maciag, M. Kubacka, S. Mogilski, B. Filipek, K. Stadnicka, and K. Kieć-Kononowicz Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin Bioorg. Med. Chem. 16 2008 5982 5998 (Pubitemid 351758841)
11. J.P. Hieble Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics Pharm. Acta. Helv. 74 2000 163 171 (Pubitemid 30182566)
12. U. Hink, M. Oelze, P. Kolb, M. Bachschmid, M.H. Zou, A. Daiber, H. Mollnau, M. August, S. Baldus, N. Tsilimingas, U. Walter, V. Ullrich, and T. Münzel Role for peroxynitrite in the inhibition of prostacyclin syntase in nitrate tolerance J. Am. Coll. Cardiol. 42 2003 1826 1834 (Pubitemid 37433665)
13. S. Jähnichen, M. Eltze, and H.H. Pertz Evidence that alpha(1B)-adrenoceptors are involved in noradrenaline-induced contractions of rat tail artery Eur. J. Pharmacol. 488 2004 157 167 (Pubitemid 38388535)
14. K.S. Jain, J.B. Bariwal, M.K. Kathiravan, M.S. Phoujdar, R.S. Sahne, B.S. Chauhan, A.K. Shah, and M.R. Yadav Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents Bioorg. Med. Chem. 16 2008 4759 4800 (Pubitemid 351625861)
15. O. Kamp, M. Metra, S. Bugatti, L. Bettari, A. Dei Cas, N. Petrini, and L. Dei Cas Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release Drugs 70 2010 41 56
16. K. Kulig, J. Sapa, D. Maciag, B. Filipek, and B. Malawska Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxypropyl]- pyrrolidin-2-one derivatives with anti-arrhythmic, hypotensive, and alpha-adrenolytic activity Arch. Pharm. (Weinheim) 340 2007 466 475 (Pubitemid 47478067)
17. W.G. Lachnit, A.M. Tran, D.E. Clarke, and A.P. Ford Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat Br. J. Pharmacol. 120 1997 819 826
18. T.S. Lee, and X. Hou Dual vasoactive effects of tolazoline on rabbit pulmonary arteries J. Cardiothorac. Vasc. Anesth. 10 1996 364 367 (Pubitemid 26130297)
19. O. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
20. R. Magnus Versuche am überlebenden Dünndarm von Säugetieren Pflügers Arch. 1904 102 123
21. B. Malawska, K. Kulig, B. Filipek, J. Sapa, D. Macia̧g, M. Zygmunt, and L. Antkiewicz-Michaluk Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-[2-hydroxy- or 1-[2-acetoxy-3-arylalkylamino)-propyl]- pyrrolidin-2-one derivatives with adrenolytic activity Eur. J. Med. Chem. 37 2002 183 195 (Pubitemid 34251182)
22. 1-adrenoceptor antagonist Il Farmaco 60 2005 793 803
23. G.A. Michelotti, and D.A. Schwinn Mechanistic insights into the role of alpha1adrenergic receptors in lower urinary tract symptoms Curr. Urol. Rep. 5 2004 258 266
24. C. Napoli, and L.J. Ignarro Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases Arch. Pharm. Res. 32 2009 1103 1108
25. A. Orisadipe, S. Amos, A. Adesomoju, L. Binda, M. Emeje, J. Okogun, C. Wambebe, and K. Gamaniel Spasmolytic activity of methyl angolensate: a triterpenoid isolated from Entandrophragma angolense Biol. Pharm. Bull. 24 2001 364 367 (Pubitemid 32377603)
26. M. Philipp, and L. Hein Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes Pharmacol. Ther. 101 2004 65 74 (Pubitemid 38068526)
27. J. Sapa, A. Nowaczyk, and K. Kulig Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties Naunyn Schmiedebergs Arch Pharmacol 2010 10.1007/s00210-010-0566-x
28. D.A. Schwinn, and C.G. Roehrborn Alpha1-adrenoceptor subtypes and lower urinary tract symptoms Int. J. Urol. 15 2008 193 199 (Pubitemid 351316928)
29. D.A. Sica Alpha1-adrenergic blockers: current usage considerations J. Clin. Hypertens. (Greenwich) 7 2005 757 762
30. G.Y. Sy, V. Bruban, P. Bousquet, and J. Feldman Nitric oxide and central antihypertensive drugs. One more difference between catecholamines and imidazolines Hypertension 37 2001 246 249 (Pubitemid 32199082)
31. D. Tsikas Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the l-arginine/nitric oxide area of research J. Chromatogr. B. 852 2007 51 70 (Pubitemid 46720134)
32. J. Vergara-Galicia, R. Ortiz-Andrade, P. Castillo-España, M. Ibarra-Barajas, I. Gallardo-Ortiz, R. Villalobos-Molina, and S. Estrada-Soto Antihypertensive and vasorelaxant activities of Laelia autumnalis are mainly through calcium channel blockade Vascul. Pharmacol. 49 2008 26 31